Search jobs 11-Feb-2021 Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine
DGAP-News: Heidelberg Pharma AG / Key word(s): Miscellaneous
11.02.2021 / 07:58
PRESS RELEASE
Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in
Science Translational Medicine
- Extraordinary efficacy of a HER2-targeting Trastuzumab-ATAC in the treatment of Triple-Negative Breast Cancer (TNBC) with low HER2 expression and hemizygous deletion of chromosome 17p in preclinical models
- Induction of immunogenic cell death by an HER2-ATAC - Synergistic and increased efficacy in combination with checkpoint inhibitors
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 .
Ayala PharmaceuticalsJanuary 28, 2021 GMT
REHOVOT, Israel and WILMINGTON, Del., Jan. 28, 2021 (GLOBE NEWSWIRE) Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the first patient dosed in the Phase 2 TENACITY clinical trial of its potent, selective small molecule AL101, for the treatment of patients with Notch-activated recurrent or metastatic (R/M) triple negative breast cancer (TNBC).
Online poetry workshops to help Sussex people living with cancer littlehamptongazette.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from littlehamptongazette.co.uk Daily Mail and Mail on Sunday newspapers.
Targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body s immune response.
A new study published in
Cell shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor cells to self-destruct as if fighting an infection. Researchers suggest this mechanism could open new avenues for turning on the immune system in aggressive cancers like TNBC. We know therapeutics that partially interfere with RNA splicing can have a very strong impact on tumor growth and progression, but the mechanisms of tumor killing are largely unknown. In this study, we discovered that these therapeutics are modulators of anti-tumor immunity, said Dr. Trey Westbrook, corresponding author of the study, executive director o
IIT Guwahati signs MoU with NECHRI Jorabat, Assam for identifying novel biomarkers for cancer diagnosis
IIT Guwahati has signed an MoU with NECHRI Jorabat, Assam for identifying novel biomarkers for cancer diagnosis, prognosis and therapy.
advertisement
UPDATED: January 14, 2021 23:42 IST
Indian Institute of Technology (IIT) Guwahati, has signed a Memorandum of Understanding (MoU) with North East Cancer Hospital and Research Institute (NECHRI), Jorabat, Assam, on Tuesday 12th January 2021 at IIT Guwahati. The collaboration between IIT Guwahati and NECHRI started in 2014.
Both IIT Guwahati and NECHRI have been engaged in identifying novel biomarkers for cancer diagnosis, prognosis, therapy and recurrence. Both the institutes have also been engaged in identifying cancer susceptible population from North East India. This collaboration has already identified novel targets for oral cancer (a leading cancer burden in India) drug discovery. This research has been published in highly